Everolimus 0.25 mg Tablet PCD Franchise, Immunosuppressant Tablet Supplier India, Everolimus Tablet Manufacturer, Transplant Rejection Medicine Distributor, Best Price Pharma Franchise

Everolimus Tablet Franchise in Ahmedabad

Immunosuppressant Tablet Distributor in Delhi

Everolimus Tablet Manufacturer in Bangalore

Transplant Medicine Tablet Stockist in Hyderabad
Everolimus Tablet Exporter in Chandigarh

Home/Products /everolimus-0-25mg-tablet

Everloop 0.25 Tablet

Composition : Everolimus (0.25mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹0/-

Everloop 0.25 Tablet contains Everolimus 0.25 mg, an mTOR inhibitor with potent immunosuppressive and antiproliferative properties. It is widely used in organ transplant patients to prevent rejection and in selected oncology indications where controlled inhibition of cell growth is required.

Everolimus works by blocking the mammalian target of rapamycin (mTOR) pathway, thereby suppressing T-cell activation and reducing abnormal cell proliferation. This mechanism helps in maintaining graft survival while minimizing immune-mediated damage.

Clinically, Everloop 0.25 Tablet is prescribed for post-transplant immunosuppression and specific tumor-related therapies, often as part of combination treatment protocols under strict medical supervision.

The tablet offers precise low-dose control, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospital use, transplant centers, and specialized clinical settings requiring long-term immune modulation.

Read More

About the Product

Everloop 0.25 Tablet contains Everolimus 0.25 mg, an mTOR inhibitor with potent immunosuppressive and antiproliferative properties. It is widely used in organ transplant patients to prevent rejection and in selected oncology indications where controlled inhibition of cell growth is required.

Everolimus works by blocking the mammalian target of rapamycin (mTOR) pathway, thereby suppressing T-cell activation and reducing abnormal cell proliferation. This mechanism helps in maintaining graft survival while minimizing immune-mediated damage.

Clinically, Everloop 0.25 Tablet is prescribed for post-transplant immunosuppression and specific tumor-related therapies, often as part of combination treatment protocols under strict medical supervision.

The tablet offers precise low-dose control, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospital use, transplant centers, and specialized clinical settings requiring long-term immune modulation.

Common side effects may include mouth ulcers, infections, fatigue, rash, diarrhea, nausea, and increased blood lipid levels. Rarely, serious effects such as impaired wound healing, lung toxicity, severe infections, or blood count abnormalities may occur.

Everloop 0.25 Tablet is indicated for the prevention of organ transplant rejection in combination with other immunosuppressants. It is also used in the treatment of specific cancers and benign tumors, such as renal cell carcinoma, neuroendocrine tumors, and tuberous sclerosis complex–associated conditions, as prescribed by a specialist.

Use Everloop 0.25 Tablet strictly under specialist supervision. Regular monitoring of blood counts, kidney function, lipid profile, and drug levels may be required. Inform your doctor if you have active infections, liver impairment, or are taking other immunosuppressive medicines. Avoid live vaccines during therapy and seek immediate medical attention if signs of infection or breathing difficulty occur.

Store below 25°C in a dry place. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation